Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.68 |
| ▸ | ESRRB | O95718 | 6/20 | 0.68 |
| ▸ | ESRRA | P11474 | 6/20 | 0.68 |
| ▸ | XDH | P47989 | 3/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.47 |
| ▸ | ADH5 | P11766 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936450 | 0.82 | ESR1 (1.00) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL15096753 | 0.79 | ESR1 (0.65) | ESR1ESR2XDHRPA1ADH5 | |
| SCHEMBL6534483 | 0.78 | ESR1 (0.84) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL1289555 | 0.78 | ESR1 (0.78) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL17091602 | 0.77 | KDM4E (0.47) | XDHRPA1ADH5NOTUMNPC1 | |
| SCHEMBL1289615 | 0.76 | ESR1 (0.49) | ESR1ESR2XDHRPA1ADH5 | |
| SCHEMBL1289625 | 0.74 | ESR1 (0.76) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL2645811 | 0.72 | ADH5 (0.75) | XDHRPA1ADH5CLK1DYRK1A | |
| SCHEMBL3929956 | 0.71 | ESR1 (1.00) | ESR1ESR2ESRRBESRRA | |
| SCHEMBL6534235 | 0.68 | ESR1 (0.67) | ESR1ESR2ESRRBESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | claimed |
| US-20170281612-A1 | Methods for the Treatment of Cystic Fibrosis | NIVALIS THERAPEUTICS, INC. | 2017-10-05 | — | — | US | claimed |
| EP-3204010-A1 | METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Nivalis Therapeutics, Inc. (US) | 2017-08-16 | — | — | EP | claimed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | claimed |
| US-9433618-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | claimed |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-08-04 | — | — | US | claimed |
| WO-2016057811-A1 | METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | NIVALIS THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | claimed |
| EP-2624695-B1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2015-09-23 | — | — | EP | claimed |
| US-9139528-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20150080429-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2015-03-19 | — | — | US | claimed |
| US-8921562-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | claimed |
| EP-2624695-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-08-14 | — | — | EP | claimed |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | claimed |
| CN-103200820-A | Novel substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-07-10 | — | — | CN | claimed |
| WO-2012048181-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-04-12 | — | — | WO | claimed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012048181-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | ESR1 1623/4885ESR2 1052/4885ESRRB 786/4885 |
| US-20170281612-A1 | Methods for the Treatment of Cystic Fibrosis | GSR, CBS, CTH | ESR1 4343/4885ESR2 3306/4885ESRRB 898/4885 |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | ESR1 1623/4885ESR2 1052/4885ESRRB 786/4885 |
| US-20150080429-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | ESR1 1623/4885ESR2 1052/4885ESRRB 786/4885 |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | ESR1 1623/4885ESR2 1052/4885ESRRB 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.